Trial Profile
Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Miltefosine (Primary) ; Meglumine antimonate
- Indications Cutaneous leishmaniasis
- Focus Therapeutic Use
- 09 Jun 2014 New trial record